PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.
Completed · Phase 1
Conditions studied: Healthy Adults
In brief
A Phase 1 Open-label, Two-cohort, One-sequence Crossover Study to Investigate the Effect of P glycoprotein Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics, Safety, and Tolerability of Sitravatinib in Healthy Subjects.
Key facts
- Study ID
- NCT05255276
- Run by
- Mirati Therapeutics Inc.
- People needed
- 36
- Starts
- 2022-02-02
- Expected to finish
- 2023-02-10
- Last updated by the study team
- 2024-05-08
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Labcorp Drug Development Clinical Research Unit — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.